Your browser doesn't support javascript.
loading
A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder, A; Ang, J E; Kyle, F; Harris, D; Rudman, S; Kristeleit, R; Solca, F; Uttenreuther-Fischer, M; Pemberton, K; Pelling, K; Schnell, D; de Bono, J; Spicer, J.
Afiliação
  • Suder A; Department of Medical Oncology, Guys and St Thomas' NHS Foundation, Great Maze Pond, London SE1 9RT, UK. Electronic address: anetasuder@hotmail.com.
  • Ang JE; Drug Development Unit, The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT UK. Electronic address: jooern.ang@icr.ac.uk.
  • Kyle F; Department of Medical Oncology, Guys and St Thomas' NHS Foundation, Great Maze Pond, London SE1 9RT, UK. Electronic address: fiona.kyle@gstt.nhs.uk.
  • Harris D; The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK. Electronic address: dean.harris@cdhb.health.nz.
  • Rudman S; Department of Medical Oncology, Guys and St Thomas' NHS Foundation, Great Maze Pond, London SE1 9RT, UK. Electronic address: sarah.rudman@gstt.nhs.uk.
  • Kristeleit R; The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK. Electronic address: r.kristeleit@ucl.ac.uk.
  • Solca F; Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer Gasse 5-11, A1120 Vienna, Austria. Electronic address: flavio.solca@boehringer-ingelheim.com.
  • Uttenreuther-Fischer M; Therapeutic Area Oncology, Boehringer Ingelheim Pharma GmbH & Co KG, Birkendorfer Str 65, Biberach an der Riss 88397, Germany. Electronic address: martina.uttenreuther-fischer@boehringer-ingelheim.com.
  • Pemberton K; Medical Department, Boehringer Ingelheim Ltd, Ellesfield Avenue, Bracknell RG12 8YS, UK. Electronic address: karine.pemberton@boehringer-ingelheim.com.
  • Pelling K; Biometrics and Data Management, Boehringer Ingelheim Ltd, Ellesfield Avenue, Bracknell RG12 8YS, UK. Electronic address: katy.pelling@boehringer-ingelheim.com.
  • Schnell D; Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim GmbH & Co KG, Birkendorfer Str 65, Biberach an der Riss, 88397 Biberach an der Riss, Germany. Electronic address: david.schnell@boehringer-ingelheim.com.
  • de Bono J; Drug Development Unit, The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT UK. Electronic address: johann.de-Bono@icr.ac.uk.
  • Spicer J; King's College London - Division of Cancer Studies, 3rd Floor, Bermondsey Wing, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK. Electronic address: james.spicer@kcl.ac.uk.
Eur J Cancer ; 51(16): 2275-84, 2015 Nov.
Article em En | MEDLINE | ID: mdl-26296295
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Quinazolinas / Protocolos de Quimioterapia Combinada Antineoplásica / Paclitaxel / Inibidores de Proteínas Quinases / Neoplasias Tipo de estudo: Clinical_trials País/Região como assunto: Europa Idioma: En Revista: Eur J Cancer Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Quinazolinas / Protocolos de Quimioterapia Combinada Antineoplásica / Paclitaxel / Inibidores de Proteínas Quinases / Neoplasias Tipo de estudo: Clinical_trials País/Região como assunto: Europa Idioma: En Revista: Eur J Cancer Ano de publicação: 2015 Tipo de documento: Article